ZEB1 shapes AML immunological niches, suppressing CD8 T cell activity while fostering Th17 cell expansion
Barbara Bassani, Giorgia Simonetti, Valeria Cancila, Antonio Fiorino, Marilena Ciciarello, Annamaria Piva, Arman Mandegar Khorasani, Claudia Chiodoni, Daniele Lecis, Alessandro Gulino, Eugenio Fonzi, Laura Botti, Paola Portararo, Massimo Costanza, Marta Brambilla, Giorgia Colombo, Juerg Schwaller, Alexandar Tzankov, Maurilio Ponzoni, Fabio Ciceri, Niccolò Bolli, Antonio Curti, Claudio Tripodo, Mario P. Colombo, Sabina Sangaletti
Abstract
patients exhibit increased IL-17, SOCS2, and TGF-β pathways and a negative association with overall survival. This unveils ZEB1's dual role in AML, entwining pro-tumoral and immune regulatory capacities in AML blasts.
Topics & Concepts
NicheCell biologyCellCD8Cytotoxic T cellBiologyImmunologyCancer researchImmune systemGeneticsEcologyIn vitroImmune Cell Function and InteractionImmunotherapy and Immune ResponsesCAR-T cell therapy research